News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health of $258 million and GAAP Net Income of $260 million GAAP Earnings …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%Bausch Health Companies Inc. is set to report second-quarter earnings, with analysts anticipating a significant profit surge. The company is expected to post earnings of $1.01 per share on revenue of $2.67 billion, driven by improving operating leverage and strategic initiatives like international expansion. …
Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …
Bausch Health Companies Inc (BHC) has a current risk assessment score of 6.07, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value of 0.42 indicates it may underperform during bull markets but experience smaller declines during bear markets. The report …
Bausch Health Companies Inc. (T.BHC) announced that its PrELIDEL (pimecrolimus) cream is now approved for listing under Alberta's public drug plan for eligible patients. Following this announcement, the company's shares are trading up by $0.09 at $6.43.
Bausch Health Companies Inc. announced that its PrELIDEL® (pimecrolimus) cream has been listed under Alberta's public drug plan, making it available for eligible patients. Following this announcement, shares of Bausch Health Companies Inc. (T.BHC) saw an increase, trading up $0.09 at $6.43.
LAVAL, QC, July 28, 2026 /PRNewswire/ -- Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible patients. ELIDEL® cream is indicated for second-line therapy …
Bausch + Lomb (BLCO) is set to report earnings tomorrow, with expectations for revenue growth of 7.2% year-on-year. The company has a strong record of beating revenue estimates, and analysts have reconfirmed their projections. Investors will be watching how BLCO performs compared to peers …
Bausch Health Companies Inc. is projected to report earnings of $1.01 per share. This information comes from an earnings preview provided by Refinitiv. The article provides a headline and directs readers to TradingView for the full article.
The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Bausch Health Cos Inc. by 5.3% in Q1 2026, selling 452,119 shares and retaining 8 million shares valued at $43.2 million. Other institutional investors adjusted their holdings, and director Frank D. Lee …
This article provides a detailed financial overview of Bausch Health Companies Inc (BHC), including its stock price, market capitalization, and key financial indicators. It presents extensive quarterly and annual data for income statements, balance sheets, and cash flow statements, along with analyst ratings. The …
Bausch Health's stock performance reflects a balance between its ongoing efforts to reduce substantial debt and the growth of key products like Xifaxan. Recent quarterly results showcase the Canadian pharmaceutical group's turnaround path while highlighting persistent leverage challenges. The company focuses on specialty pharma …
RBC Capital has reiterated its Hold rating on Bausch Health (BHC.US) and maintained its target price of $9. This indicates that the firm does not anticipate significant upward or downward movement in the stock price from its current levels.
Bausch Health Cos (NYSE:BHC) hit a new 52-week low of $4.35, extending recent stock weakness, with analyst sentiment remaining cautious. RBC lowered its price target to $9, and the consensus rating is "Reduce" with an $8 target price. The company reported mixed earnings, missed …
RBC Capital Markets analysts estimate Bausch Health (NYSE:BHC) will report consolidated revenue of $2.73 billion for the second quarter of 2026. This forecast reflects a potential decrease from the previous quarter, with detailed breakdowns for various segments of the company. The report includes earnings …
Bausch Health Companies Inc. stock has reached a 52-week low of $4.56, marking a significant decline of 28.42% over the past year. Despite this downturn, analysts project potential with price targets ranging from $6 to $9, and InvestingPro data suggests the stock is currently …
Bausch + Lomb has introduced Orphia, an AI-powered digital health platform within its new Digital Health Services division. Developed with Hippocratic AI, Orphia aims to reduce administrative burdens for eye care providers, starting with pre-surgery cataract education. The platform is brand agnostic, designed to …
Bausch Health Companies Inc. executive Aimee J. Lenar, President, US Pharma, had 5,260 common shares withheld for tax obligations on July 17, 2026, at a price of $4.83 per share. This withholding was due to the vesting of Restricted Share Units. Following this transaction, …
Sharemaestro market context Price above Trend Line 52 weeks -13.1%This article provides a coupon profile for the Bausch Health Companies Inc. bond, BHC4928364, which offers a 5.25% interest rate. It details that the next payment is scheduled for Jul 30, 2026, and offers an overview of the bond's interest payments and redemption information. …
This article provides a detailed profile of the BHC4928364 bond issued by Bausch Health Companies Inc., a 5.25% bond maturing on January 30, 2030. It covers key financial metrics including issue date, maturity date, outstanding amount, face value, and coupon rate. The profile also …
Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a tax-withholding disposition of 23,395 common shares on July 15, 2026, at $4.89 per share. These shares were withheld by the issuer to cover tax obligations on vested Restricted Share Units. Following …
Search by ticker symbol or company name and select a result to open its chart.